Skip to content

Virtual Reality Therapy for Improving Caregiver and Patient Quality of Life in Home-Based Palliative Care in Saudi Arabia

Virtual Reality Nature Therapy for Palliative Patients and Caregivers in Saudi Arabia: A Randomized Controlled Trial to Support Quality of Life and Cultural Adaptation

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07567391
Acronym
VIRTIC-Hajj
Enrollment
100
Registered
2026-05-05
Start date
2026-10-20
Completion date
2027-09-01
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caregivers, Palliative Care, Quality of Life, Virtual Reality

Keywords

Virtual Reality, Palliative Care, Quality of Life, Caregivers

Brief summary

This randomized controlled trial evaluates the efficacy of a culturally adapted virtual reality (VR) nature therapy intervention aimed at improving the quality of life (QOL) and emotional well-being of palliative patients and their family caregivers in Saudi Arabia. The study involves immersive VR sessions depicting natural environments, including Saudi-specific landscapes, delivered to patient-caregiver dyads at home. Outcomes include self-reported QOL measures, psychophysiological parameters, and qualitative feedback.

Detailed description

This randomized controlled trial investigates the impact of immersive Virtual Reality (VR) nature therapy on quality of life and emotional well-being among palliative care patients and their caregivers in Saudi Arabia. The intervention includes culturally adapted, high-fidelity VR nature environments designed to promote psychological comfort, reduce stress, and provide sensory engagement aligned with local preferences. Participants-dyads of patients and their primary caregivers-will be randomly assigned to either the VR intervention group or a waitlist control group. The study explores outcomes such as changes in quality of life, anxiety, and emotional support using validated patient-reported outcome measures. This trial is among the first in the region to evaluate digital interventions for supportive care in palliative settings and aims to inform scalable, culturally relevant approaches to holistic symptom management in advanced illness.

Interventions

DEVICEImmersive Nature VR

The VR intervention will consist of a series of sessions using high-resolution VR headsets and user-friendly handheld controllers. The virtual environments will include six immersive nature scenes-three tailored to Saudi cultural preferences (e.g., desert oases, wadis, and Mecca-related sites), and three universally calming settings (e.g., beach, forest, and mountain landscapes). The intervention is designed to offer therapeutic sensory engagement and emotional respite.

Sponsors

University of Bisha
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

This study will conduct an RCT to evaluate the effectiveness of culturally adapted immersive nature VR interventions for palliative patients and their caregivers in Saudi Arabia. Approximately 100 participants will be randomized into an intervention group, which will receive immersive VR nature therapy sessions, or a control group, which will receive a treatment as usual. The VR intervention will feature six natural environments, tailored to cultural preferences, including Saudi-specific landscapes (e.g., desert oases, wadis, holy sites) alongside universal nature settings (beach, forest, mountains) using high quality VR headsets, equipped with user-friendly controllers. Psycho-physiological biomarkers, such as heart rate, heart rate variability (HRV), and breathing patterns, will be measured using brain sensing headband (e.g., MUSE 2 headband).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (≥18 years) receiving palliative care in Saudi Arabia * Primary family caregivers living with and providing daily care to the patient * Ability to provide informed consent * Fluent in Arabic

Exclusion criteria

* Severe cognitive impairment or psychiatric conditions that prevent use of VR * History of epilepsy or vestibular disorders * Inability to understand or follow instructions for using VR equipment

Design outcomes

Primary

MeasureTime frameDescription
Change in Quality of Life (PROMIS-29)Baseline (Week 0) and Week 5 (post-intervention)The PROMIS-29 assesses health-related quality of life across seven domains: physical function, anxiety, depression, fatigue, sleep disturbance, social participation, and pain interference. Each domain is scored on a standardized T-score scale ranging from 0 to 100. Higher scores indicate better functioning for physical function and social participation domains, and worse symptoms for anxiety, depression, fatigue, pain interference, and sleep disturbance.
Change in Heart Rate Variability (HRV)Baseline (Week 0) and Week 5 (Post-intervention)Heart rate variability (HRV) will be measured using the MUSE 2 headband. HRV metrics will be recorded prior to the first VR session (baseline) and during intervention sessions. Analysis will compare HRV at baseline and at the end of the intervention. Higher HRV values indicate better autonomic nervous system regulation and greater stress resilience.

Secondary

MeasureTime frameDescription
Caregiver Stress and Emotional StateBaseline (Week 0) and Week 5 (post-intervention)Caregiver stress and emotional distress will be assessed using validated self-report scales (e.g., perceived stress and emotional distress measures). Higher scores indicate greater levels of stress and emotional burden.
Participant Engagement and Satisfaction (Qualitative)Week 5 (post-intervention)Semi-structured interviews will be conducted to explore participant engagement, acceptability, emotional impact, and cultural relevance of the VR intervention. Interviews will be conducted by trained research staff and analyzed using qualitative methods

Contacts

CONTACTMohammed O Alanazi, PhD
malanazi@ub.edu.sa+966533993350
PRINCIPAL_INVESTIGATORMohammed O Alanazi, PhD

University of Bisha

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026